**Dr. Murray Sheldon Associate Director for Technology and Innovation, CDRH, FDA**

Dr. Murray Sheldon's primary focus is to work with staff, the medical device industry, the clinical community and others on ways to facilitate bringing innovative medical devices to patients in the US. A significant element of this initiative has been the Entrepreneurs in Residence Program, under which outside experts worked at CDRH with CDRH staff on important public health projects. These external experts helped FDA develop new approaches, test them and then adopt those with the greatest potential. One aspect from the EiR group that Dr. Sheldon currently leads is the Reimbursement Task Force; identifying methods to streamline the path from FDA approval to reimbursement.

Dr. Sheldon received his medical degree from the University of Michigan Medical School in 1975. He completed his general surgical residency with Kaiser Permanente Medical Center in Oakland and his cardiovascular fellowships at the University of California, Davis and the Montefiore Hospital and Medical Center in New York. In 1983, he entered private practice as a staff surgeon in several medical centers in Northern California performing cardiac, thoracic and vascular surgery.

In 2003, he chose to pursue a different career path and became engaged in a highly productive career in the medical device industry leading device development projects and providing expert consultative services to numerous device development firms. From 2003-2009, Murray was the Medical Director for Arbor Surgical Technologies, (since sold to Medtronic, Inc.). At Arbor Surgical Technologies he was involved in the design and development of aortic valve devices such as a unique two-piece, sutureless aortic valve for clinical aortic valve replacement, and worked with five European surgical groups in Germany, Poland, and Russia on the implantation of the aortic valve. That company was sold to Medtronic, Inc. He has also been a Medical Director and/or Consultant to a half dozen other companies in the cardiovascular space.

Most recently, prior to joining FDA, he was the Medical Director for the minimally invasive surgical program at BioVentrix, Inc. and has developed a catheter-based procedure for surgical ventricular reconstruction for heart failure patients. This device has recently obtained a CE mark in Europe. He was also the Medical Director for Solinas Medical, Inc. and was instrumental in developing a unique device for dialysis access. That device has recently received two 510 (k) clearances.